Investor · 1 deal
Oslo
Every published round Coalition for Epidemic Preparedness Innovations took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Vaxxas | Grant | 19 Jan 2023 | ≤$6.4m | Lead | @AuManufacturing (Fri 20 Jan 2023), Brandon BioCatalyst portfolio, Brandon Capital portfolio, @AuManufacturing (Thu 19 Jan 2023) |
Companies Coalition for Epidemic Preparedness Innovations has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Vaxxas | 19 Jan 2023, Grant | 1 | 1 |
Fund closes reported for Coalition for Epidemic Preparedness Innovations, as distinct from the investments it has made.
Companies Coalition for Epidemic Preparedness Innovations has backed that another company then bought. An exit for the holding, not a deal Coalition for Epidemic Preparedness Innovations did.
Stories naming Coalition for Epidemic Preparedness Innovations. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia
Vaxxas hires former Pfizer medical executive Dr Rochelle Chaiken as its chief medical officer; the announcement also recounts the biotech's founding financing and later rounds.
Roundup of manufacturing news: Vaxxas secures CEPI funding and a CRC-P grant, Hastings gains an increased NAIF loan, Bio-Gene receives an R&D tax incentive, plus jobs data and a skills consultation.